多发性硬化症的疾病修正治疗和 SARS-CoV-2 疫苗接种：专家共识。
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
机构信息
Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Unit of Neurology, IRCCS Neuromed, Pozzilli (IS), Italy.
出版信息
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
Abstract
Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal ( https://coronavirus.jhu.edu/map.html ). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.
摘要
冠状病毒病（COVID-19）于 2019 年 12 月在中国武汉市出现，并迅速成为全球性大流行。该疾病由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起，这是一种 RNA 乙型冠状病毒，在系统发育上与严重急性呼吸系统综合征冠状病毒相似。迄今为止，全世界已记录超过 1.32 亿例 COVID-19 病例，其中超过 280 万人死亡（https://coronavirus.jhu.edu/map.html）。自 2020 年底以来，全球已开始大规模接种疫苗。疫苗的出现引起了一些神经科医生对接受免疫调节或免疫抑制治疗的多发性硬化症（MS）患者疫苗接种安全性和有效性的关注。
相似文献
1
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.多发性硬化症的疾病修正治疗和 SARS-CoV-2 疫苗接种：专家共识。
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
2
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.多发性硬化症的疾病修正治疗与 COVID-19 大流行：感染风险和未来疫苗接种的影响。
CNS Drugs. 2020 Sep;34(9):879-896. doi: 10.1007/s40263-020-00756-y.
3
[Vaccination against SARS-CoV-2 in patients with multiple sclerosis].[多发性硬化症患者的新型冠状病毒2型疫苗接种]
Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588/rn.7207.2021097.
4
Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.COVID-19 时代的多发性硬化症：疾病进程、DMT 药物和 SARS-CoV2 疫苗接种。
Curr Opin Neurol. 2022 Jun 1;35(3):319-327. doi: 10.1097/WCO.0000000000001066.
5
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.抗 SARS-CoV-2 疫苗接种在多发性硬化症患者中的应用：一年来的经验教训。
Front Immunol. 2022 Oct 17;13:1045101. doi: 10.3389/fimmu.2022.1045101. eCollection 2022.
6
COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.接受疾病修正治疗的多发性硬化症患者的COVID-19疫苗接种：实际问题。
Drugs Today (Barc). 2022 Dec;58(12):605-620. doi: 10.1358/dot.2022.58.12.3455368.
7
Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study.严重急性呼吸综合征冠状病毒 2 型大流行时期自身免疫性疾病患者的疫苗接种设定：以多发性硬化症患者为例的纵向多中心研究。
Eur Neurol. 2022;85(2):104-111. doi: 10.1159/000519582. Epub 2021 Nov 5.
8
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis.新型冠状病毒疫苗在多发性硬化症患者中的应用方法。
Front Immunol. 2021 Jun 21;12:701752. doi: 10.3389/fimmu.2021.701752. eCollection 2021.
9
Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.多发性硬化症患者 COVID 疫苗接种的安全性和有效性总结。
Eur Neurol. 2023;86(4):263-276. doi: 10.1159/000529982. Epub 2023 Mar 4.
10
A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.奥密克戎变异株早期完全接种疫苗的多发性硬化症接受抗 CD20 治疗患者 COVID-19 后血清转换的回顾性评估。
Mult Scler Relat Disord. 2023 Mar;71:104574. doi: 10.1016/j.msard.2023.104574. Epub 2023 Feb 15.
引用本文的文献
1
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of Protection.多发性硬化症患者的新冠病毒疫苗加强针：改善严重急性呼吸综合征冠状病毒2交叉变异抗体反应及保护效果预测
Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200443. doi: 10.1212/NXI.0000000000200443. Epub 2025 Jul 22.
2
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.高效多发性硬化症疗法对B细胞的影响。
Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606.
3
COVID-19 vaccination in patients with multiple sclerosis: what you need to know - a review.多发性硬化症患者的新冠病毒疫苗接种：你需要了解的内容——一篇综述
Health Sci Rep. 2024 Oct 6;7(10):e70119. doi: 10.1002/hsr2.70119. eCollection 2024 Oct.
4
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients.免疫衰老与疫苗效力：通过对多发性硬化症患者 SARS-CoV-2 特异性细胞的免疫代谢分析揭示
**请注意**：以上译文仅供参考，具体内容可根据实际情况进行调整。
Nat Commun. 2024 Mar 29;15(1):2752. doi: 10.1038/s41467-024-47013-0.
5
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.多发性硬化症中靶向 CD20 的药物：药理学、疗效、安全性和耐受性。
Drugs. 2024 Mar;84(3):285-304. doi: 10.1007/s40265-024-02011-w. Epub 2024 Mar 14.
6
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.多发性硬化症患者对 SARS-CoV-2 mRNA 疫苗的体液和 T 细胞反应：与 DMTs 和临床变量的相关性。
Neurotherapeutics. 2024 Mar;21(2):e00307. doi: 10.1016/j.neurot.2023.e00307. Epub 2023 Dec 19.
7
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.ECTRIMS/EAN 关于多发性硬化症患者接种疫苗的共识：在高度活跃的免疫治疗药物时代改进免疫策略。
Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9.
8
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.T 细胞对 SARS-CoV-2 疫苗接种的反应因多发性硬化症的疾病修正治疗而异。
JCI Insight. 2023 Jun 22;8(12):e165111. doi: 10.1172/jci.insight.165111.
9
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.第三剂 SARS-CoV-2 疫苗在接受不同疾病修正治疗的多发性硬化症患者中的体液疗效。
Mult Scler Relat Disord. 2022 Dec;68:104371. doi: 10.1016/j.msard.2022.104371. Epub 2022 Oct 23.
10
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC).评估西尼莫德治疗患者对SARS-CoV-2 mRNA疫苗的免疫反应：一项非随机对照临床试验（AMA-VACC）。
Ther Adv Neurol Disord. 2022 Nov 8;15:17562864221135305. doi: 10.1177/17562864221135305. eCollection 2022.
本文引用的文献
1
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.来自MAGNIFY-MS研究中接受克拉屈滨片治疗的高度活动性复发型多发性硬化症患者的水痘带状疱疹病毒和流感疫苗抗体滴度。
Mult Scler. 2022 Nov;28(13):2151-2153. doi: 10.1177/13524585221099413. Epub 2022 Jun 7.
2
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
3
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.接受利妥昔单抗治疗的炎症性风湿和肌肉骨骼疾病患者的COVID-19结局：一项队列研究。
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
4
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.多发性硬化症患者的 COVID-19：与疾病修正治疗的关联
CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20.
5
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.北美多发性硬化症患者SARS-CoV-2感染的相关结局和风险因素
JAMA Neurol. 2021 Jun 1;78(6):699-708. doi: 10.1001/jamaneurol.2021.0688.
6
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.使用富马酸二甲酯治疗的多发性硬化症患者中的新型冠状病毒肺炎。
J Neurol. 2021 Sep;268(9):3132-3134. doi: 10.1007/s00415-021-10446-4. Epub 2021 Feb 20.
7
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.COVID-19 与中枢神经系统脱髓鞘疾病患者的疾病修正治疗：系统评价。
Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.
8
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.疾病修正疗法与多发性硬化症中 2019 年冠状病毒病严重程度。
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
9
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.COVID-19 在多发性硬化症接受特立氟胺治疗的患者中的病例报告和文献复习。
Mult Scler Relat Disord. 2021 Feb;48:102734. doi: 10.1016/j.msard.2020.102734. Epub 2021 Jan 2.
10
Neurological infection with SARS-CoV-2 - the story so far.SARS-CoV-2 引起的神经系统感染——迄今的研究进展。
Nat Rev Neurol. 2021 Feb;17(2):65-66. doi: 10.1038/s41582-020-00453-w.
Zotero 插件